The National Coalition for Cancer Survivorship has submitted comments to CMS, providing feedback on the Merit-Based Incentive Payment System and Alternative Payment Models proposed by CMS as it transitions toward value-based reimbursement.
The National Coalition for Cancer Survivorship (NCCS) has submitted comments to CMS, providing feedback on the Merit-Based Incentive Payment System (MIPs) and Alternative Payment Models (APMs) proposed by CMS as it transitions toward value-based reimbursement.
NCCS is an advocacy organization founded by cancer survivors and represents the voice of cancer patients and survivors. The organizations strives to improve the quality of care and quality of life for this population by promoting policy changes via partnerships with payers, care providers, National Committee for Quality Assurance, and the Patient-Centered Outcomes Research Institute.
In a response letter to the CMS, NCCS has addressed the following concerns with CMS’ reform proposal:
1. APMs for Cancer Care
While agreeing that the patient-centered oncology medical home (PCOMH) is a true value-based APM, NCCS recommends that CMS should design a variation to PCOMH that caters to the needs and requirements of survivors who are not undergoing active treatment. “Just as PCOMH models have transformed active cancer treatment for certain populations of cancer patients, the PCOMH approach holds promise for transforming survivorship care,” they write in their letter.
While appreciating the complexity of developing physician reimbursement models that focus on specific patient populations, the letter makes the point that cancer survivors are an exponential population among Medicare beneficiaries—what with innovative and better treatment options and care regimens—which calls for efforts to design a mode flexible APM.
2. Clinical Practice Improvement Activities Performance
NCCS recommends that Medicare Access and CHIP Reauthorization Act should include cancer treatment planning and coordination as a subcategory under the clinical practice improvement category of MIPS. NCCS has been very actively working to establish a payment code for cancer care planning, so it’d be easier for cancer care providers to claim payment for the time they spend with their patient to develop a care plan, which they believe, can have a significant impact on patient outcomes. NCCS, in the letter, has recommended CMS to include the following elements in MIPS:
· Shared decision-making that considers treatment gals and outline all elements of active treatment and symptom management in a written plan
· Coordination of multidisciplinary cancer care
· Appropriate management of side effects of the treatments and symptoms of cancer.
Describing it as a process measure, NCCS believes cancer care providers can provide information on treatment planning and coordination. Patient input to this subcategory can be gained through a Consumer Assessment of Healthcare Providers and Systems or CAHPS item, they propose.
3. Resource Use
NCCS has urged CMS to be conscious of the rapid pace of innovation in the cancer drug development industry, and to consider this when measuring resource utilization. Highlighting the importance of molecular diagnostics and targeted treatments in improving outcomes, the letter highlights the need for a fair balance between healthcare utilization and patient access.
“A resource use measure that took molecular diagnosis into account might help to protect against both underutilization and overutilization of targeted treatments and encourage progress toward delivery of the right treatment to the right patient at the right time,” they write.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More